Buckhead Capital Management LLC Cuts Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Buckhead Capital Management LLC lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 9.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,149 shares of the medical research company's stock after selling 1,961 shares during the period. Buckhead Capital Management LLC's holdings in Charles River Laboratories International were worth $3,535,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Wolff Wiese Magana LLC bought a new position in shares of Charles River Laboratories International during the third quarter valued at about $32,000. Versant Capital Management Inc lifted its position in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after buying an additional 150 shares in the last quarter. Assetmark Inc. lifted its position in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock worth $37,000 after buying an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. boosted its stake in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after buying an additional 65 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of Charles River Laboratories International in the third quarter valued at approximately $59,000. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

NYSE CRL traded down $1.10 on Monday, hitting $152.07. The stock had a trading volume of 841,129 shares, compared to its average volume of 1,002,698. The firm has a 50-day moving average of $175.44 and a 200-day moving average of $189.72. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $275.00. The company has a market capitalization of $7.78 billion, a price-to-earnings ratio of 19.03, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37.

Wall Street Analyst Weigh In

Several research firms have weighed in on CRL. Evercore ISI boosted their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. cut their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating on the stock in a report on Monday, February 3rd. TD Cowen increased their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research report on Monday, November 11th. Morgan Stanley lowered their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. Finally, CLSA cut shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target on the stock. in a report on Monday, November 18th. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, Charles River Laboratories International currently has a consensus rating of "Hold" and an average price target of $200.79.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).